EGFR and cancer: In addition, we found a significant over-representation of miR-1246 targets in several KEGG pathways including pathways in cancer (FDR-corrected P value = 6.37 × 10–09), EGFR tyrosine kinase inhibitor resistance (FDR-corrected P value = 2.02 × 10–06), PI3K-Akt signalling pathway (FDR-corrected P value = 1.06 × 10–06), signalling pathway regulating pluripotency of stem cells (FDR-corrected P value = 6.04 × 10–05), and MAPK signalling pathway (FDR-corrected P value = 1.76 × 10–05) (Fig. 4B).